Abstract
ObjectiveTo investigate whether the reproductive outcomes of oocytes with smooth endoplasmic reticulum aggregates (SERa) are impaired.MethodsA total of 2893 intracytoplasmic sperm injection (ICSI) cycles were performed between January 2010 and December 2019 in our center. In 43 transfer cycles, transferred embryos were totally derived from SERa+ oocytes. Each of the 43 cycles was matched with a separate control subject from SERa- patient of the same age ( ± 1 year), embryo condition, main causes of infertility, type of protocols used for fresh or frozen embryo transfer cycles. The clinical pregnancy, implantation, ectopic pregnancy and live birth rate were compared between the two groups.Results43 embryo transfer cycles from SERa- patient were matched to the 43 transferred cycles with pure SERa+ oocytes derived embryos. No significant difference was observed in clinical pregnancy rate (55.81% vs. 65.11%, p=0.5081), implantation rate (47.89% vs. 50.70%, p=0.8667) and live birth rate (48.84% vs. 55.81%, p=0.6659) between the SERa+ oocyte group and the matched group. No congenital birth defects were found in the two groups.ConclusionOur results suggest that the implantation, clinical pregnancy, live birth and birth defects rate of embryos derived from oocytes with SERa are not impaired.
Highlights
Aggregates of smooth endoplasmic reticulum (SERa) in the ooplasm is one of the cytoplasmic dysmorphisms of oocytes
43 embryo transfer cycles from smooth endoplasmic reticulum aggregates (SERa)- patient were matched to the 43 transferred cycles with pure SERa+ oocytes derived embryos
No significant difference was observed in clinical pregnancy rate (55.81% vs. 65.11%, p=0.5081), implantation rate (47.89% vs. 50.70%, p=0.8667) and live birth rate (48.84% vs. 55.81%, p=0.6659) between the SERa+ oocyte group and the matched group
Summary
Aggregates of smooth endoplasmic reticulum (SERa) in the ooplasm is one of the cytoplasmic dysmorphisms of oocytes. SERa+ Oocytes on Reproductive Outcomes several studies have shown that significantly reduced pregnancy rates and a comparatively high number of congenital abnormalities in live born babies derived from SERa+ oocytes and/or cycles (1, 3, 4). Due to these adverse fetal outcomes, the Istanbul consensus in 2011 recommended not to use SERa+ oocytes (5). It was showed that there was no increase in congenital anomalies in embryos derived from SERa+ cycles and/or oocytes (6–9) Due to these discordant conclusions, reproductive endocrinologists and embryologists have varying attitudes when managing SERa+ oocytes. The revised Vienna Alpha/ESHRE consensus reconsidered the recommendation and advised a case by case approach in 2017 (15)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
